Cargando…
The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression
BACKGROUND: RNA N6-Methyladenosine (m6A) modification is implicated in the progression of human cancers including cholangiocarcinoma (CCA). METTL16 is recently identified as a new RNA methyltransferase responsible for m6A modification, although the role of METTL16 in CCA has not yet been examined. T...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566113/ https://www.ncbi.nlm.nih.gov/pubmed/37817227 http://dx.doi.org/10.1186/s13046-023-02844-5 |
_version_ | 1785118850303393792 |
---|---|
author | Liu, Nianli Zhang, Jinqiang Chen, Weina Ma, Wenbo Wu, Tong |
author_facet | Liu, Nianli Zhang, Jinqiang Chen, Weina Ma, Wenbo Wu, Tong |
author_sort | Liu, Nianli |
collection | PubMed |
description | BACKGROUND: RNA N6-Methyladenosine (m6A) modification is implicated in the progression of human cancers including cholangiocarcinoma (CCA). METTL16 is recently identified as a new RNA methyltransferase responsible for m6A modification, although the role of METTL16 in CCA has not yet been examined. The current study aims to investigate the effect and mechanism of the RNA methyltransferase METTL16 in CCA. METHODS: The expression of METTL16 in CCA was examined by analyzing publicly available datasets or by IHC staining on tumor samples. siRNA or CRISPR/Cas9-mediated loss of function studies were performed in vitro and in vivo to investigate the oncogenic role of METTL16 in CCA. MeRIP-Seq was carried out to identify the downstream target of METTL16. ChIP-qPCR, immunoprecipitation, and immunoblots were used to explore the regulation mechanisms for METTL16 expression in CCA. RESULTS: We observed that the expression of METTL16 was noticeably increased in human CCA tissues. Depletion of METTL16 significantly inhibited CCA cell proliferation and decreased tumor progression. PRDM15 was identified as a key target of METTL16 in CCA cells. Mechanistically, our data showed that METTL16 regulated PRDM15 protein expression via YTHDF1-dependent translation. Accordingly, we observed that restoration of PRDM15 expression could rescue the deficiency of CCA cell proliferation/colony formation induced by METTL16 depletion. Our subsequent analyses revealed that METTL16-PRDM15 signaling regulated the expression of FGFR4 in CCA cells. Specifically, we observed that PRDM15 protein was associated with the FGFR4 promoter to regulate its expression. Furthermore, we showed that the histone acetyltransferase p300 cooperated with the transcription factor YY1 to regulate METTL16 gene expression via histone H3 lysine 27 (H3K27) acetylation in CCA cells. CONCLUSIONS: This study describes a novel METTL16-PRDM15-FGFR4 signaling axis which is crucial for CCA growth and may have important therapeutic implications. We showed that depletion of METTL16 significantly inhibited CCA cell proliferation and decreased tumor progression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02844-5. |
format | Online Article Text |
id | pubmed-10566113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105661132023-10-12 The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression Liu, Nianli Zhang, Jinqiang Chen, Weina Ma, Wenbo Wu, Tong J Exp Clin Cancer Res Research BACKGROUND: RNA N6-Methyladenosine (m6A) modification is implicated in the progression of human cancers including cholangiocarcinoma (CCA). METTL16 is recently identified as a new RNA methyltransferase responsible for m6A modification, although the role of METTL16 in CCA has not yet been examined. The current study aims to investigate the effect and mechanism of the RNA methyltransferase METTL16 in CCA. METHODS: The expression of METTL16 in CCA was examined by analyzing publicly available datasets or by IHC staining on tumor samples. siRNA or CRISPR/Cas9-mediated loss of function studies were performed in vitro and in vivo to investigate the oncogenic role of METTL16 in CCA. MeRIP-Seq was carried out to identify the downstream target of METTL16. ChIP-qPCR, immunoprecipitation, and immunoblots were used to explore the regulation mechanisms for METTL16 expression in CCA. RESULTS: We observed that the expression of METTL16 was noticeably increased in human CCA tissues. Depletion of METTL16 significantly inhibited CCA cell proliferation and decreased tumor progression. PRDM15 was identified as a key target of METTL16 in CCA cells. Mechanistically, our data showed that METTL16 regulated PRDM15 protein expression via YTHDF1-dependent translation. Accordingly, we observed that restoration of PRDM15 expression could rescue the deficiency of CCA cell proliferation/colony formation induced by METTL16 depletion. Our subsequent analyses revealed that METTL16-PRDM15 signaling regulated the expression of FGFR4 in CCA cells. Specifically, we observed that PRDM15 protein was associated with the FGFR4 promoter to regulate its expression. Furthermore, we showed that the histone acetyltransferase p300 cooperated with the transcription factor YY1 to regulate METTL16 gene expression via histone H3 lysine 27 (H3K27) acetylation in CCA cells. CONCLUSIONS: This study describes a novel METTL16-PRDM15-FGFR4 signaling axis which is crucial for CCA growth and may have important therapeutic implications. We showed that depletion of METTL16 significantly inhibited CCA cell proliferation and decreased tumor progression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02844-5. BioMed Central 2023-10-11 /pmc/articles/PMC10566113/ /pubmed/37817227 http://dx.doi.org/10.1186/s13046-023-02844-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Liu, Nianli Zhang, Jinqiang Chen, Weina Ma, Wenbo Wu, Tong The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression |
title | The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression |
title_full | The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression |
title_fullStr | The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression |
title_full_unstemmed | The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression |
title_short | The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression |
title_sort | rna methyltransferase mettl16 enhances cholangiocarcinoma growth through prdm15-mediated fgfr4 expression |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566113/ https://www.ncbi.nlm.nih.gov/pubmed/37817227 http://dx.doi.org/10.1186/s13046-023-02844-5 |
work_keys_str_mv | AT liunianli thernamethyltransferasemettl16enhancescholangiocarcinomagrowththroughprdm15mediatedfgfr4expression AT zhangjinqiang thernamethyltransferasemettl16enhancescholangiocarcinomagrowththroughprdm15mediatedfgfr4expression AT chenweina thernamethyltransferasemettl16enhancescholangiocarcinomagrowththroughprdm15mediatedfgfr4expression AT mawenbo thernamethyltransferasemettl16enhancescholangiocarcinomagrowththroughprdm15mediatedfgfr4expression AT wutong thernamethyltransferasemettl16enhancescholangiocarcinomagrowththroughprdm15mediatedfgfr4expression AT liunianli rnamethyltransferasemettl16enhancescholangiocarcinomagrowththroughprdm15mediatedfgfr4expression AT zhangjinqiang rnamethyltransferasemettl16enhancescholangiocarcinomagrowththroughprdm15mediatedfgfr4expression AT chenweina rnamethyltransferasemettl16enhancescholangiocarcinomagrowththroughprdm15mediatedfgfr4expression AT mawenbo rnamethyltransferasemettl16enhancescholangiocarcinomagrowththroughprdm15mediatedfgfr4expression AT wutong rnamethyltransferasemettl16enhancescholangiocarcinomagrowththroughprdm15mediatedfgfr4expression |